FDA Direct Final Rule Scrubs "Animal Testing" Language from Drug-Development Regulations — Nonclinical Alternatives Formalized
On September 21, 2026, the FDA issued a direct final rule updating its regulations so that non-animal methods can be used where appropriate for pre-human safety testing of drugs and biologics. The rule replaces terms like "animal tests" and "animal studies" with "nonclinical tests" and "nonclinical studies" (and swaps "preclinical" and "in vitro" as well), defining "nonclinical test/study" in line with the Food and Drug Omnibus Reform Act of 2022 (FDORA), which already recognized both animal studies and newer non-animal methods as ways to generate the evidence needed to begin human trials.
The substantive core: the rule "removes language that could suggest that animal testing is the only acceptable way to generate safety information for regulatory decisions in products intended for human use1." The FDA is explicit about limits — it "does not eliminate or prohibit animal studies, change evidentiary standards or impose new costs or requirements on drug developers." Acting FDA Commissioner of Food and Drugs Kyle Diamantas: "This new rule supports the Trump Administration's push to explore ways to complement, or where appropriate, replace animal studies with methods that may better predict how medicines will actually affect people... Our goal is not to replace one rigid approach with another."
The agency also launched a New Approach Methodologies (NAMs) database with 25 use-case examples drawn from public FDA review materials, and published a companion proposed rule so rulemaking can proceed via the standard process if significant adverse comments force withdrawal of the direct final rule. The FDA frames both actions as complementing Operation TrialBlazer, HHS's clinical-research modernization initiative (see FDA Launches Expedited IND Pilot Under Operation TrialBlazer — Applications Open Through October 30, 2026).
What it means: Terminology sounds cosmetic, but in regulation it isn't — the words "animal studies" in 21 CFR provisions have functioned as a default requirement, and replacing them with FDORA's "nonclinical tests" gives sponsors a clear regulatory basis to substitute organ-on-chip, human-cell and computational models where validated. Watch for industry uptake and any adverse comments that force the companion-rule path.
-
An instance of Computational design is replacing empirical screening in drug and vaccine development. — The rulemaking gives organ-on-chip, human-cell and computational substitutes formal regulatory standing in place of empirical animal screening. ↩︎